PYA Waltman Capital LLC Purchases 3,983 Shares of Amgen Inc. $AMGN

PYA Waltman Capital LLC increased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 29.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 17,735 shares of the medical research company’s stock after purchasing an additional 3,983 shares during the quarter. Amgen makes up about 1.6% of PYA Waltman Capital LLC’s holdings, making the stock its 16th biggest position. PYA Waltman Capital LLC’s holdings in Amgen were worth $6,422,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AMGN. Anfield Capital Management LLC boosted its stake in shares of Amgen by 1,000.0% in the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after buying an additional 70 shares during the last quarter. Dogwood Wealth Management LLC increased its position in shares of Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 55 shares during the last quarter. Tower View Wealth Management LLC lifted its holdings in Amgen by 331.6% during the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock worth $29,000 after acquiring an additional 63 shares during the period. Manning & Napier Advisors LLC lifted its holdings in Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after acquiring an additional 32 shares during the period. Finally, Evergreen Advisors LLC purchased a new position in Amgen in the first quarter worth $37,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Activity

In other news, SVP Rachna Khosla sold 2,000 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total value of $825,140.00. Following the sale, the senior vice president directly owned 6,404 shares of the company’s stock, valued at approximately $2,642,098.28. This represents a 23.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the sale, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 6,222 shares of company stock valued at $2,540,926. 0.85% of the stock is owned by corporate insiders.

Amgen Trading Up 1.9%

Shares of AMGN stock opened at $438.12 on Wednesday. The stock has a market capitalization of $236.86 billion, a price-to-earnings ratio of 27.23, a PEG ratio of 3.10 and a beta of 0.43. The company’s fifty day simple moving average is $392.17 and its two-hundred day simple moving average is $365.59. Amgen Inc. has a 1 year low of $269.77 and a 1 year high of $447.03. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. The firm had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The business’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same period last year, the company earned $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, analysts anticipate that Amgen Inc. will post 22.97 earnings per share for the current year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be paid a $2.52 dividend. The ex-dividend date is Friday, August 21st. This represents a $10.08 annualized dividend and a yield of 2.3%. Amgen’s dividend payout ratio (DPR) is currently 62.65%.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Cantor Fitzgerald upped their price objective on Amgen from $350.00 to $400.00 and gave the company a “neutral” rating in a research note on Tuesday, August 18th. Mizuho boosted their price target on shares of Amgen from $303.00 to $352.00 and gave the stock a “neutral” rating in a report on Tuesday, August 18th. Guggenheim increased their price target on shares of Amgen from $343.00 to $388.00 and gave the company a “neutral” rating in a research report on Monday, August 10th. Morgan Stanley reaffirmed an “overweight” rating and issued a $362.00 price objective on shares of Amgen in a research report on Wednesday, August 19th. Finally, Scotiabank increased their target price on shares of Amgen from $385.00 to $450.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have issued a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, Amgen presently has a consensus rating of “Hold” and an average target price of $380.43.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Repatha delivers potentially market-expanding cardiovascular data. Amgen reported that Repatha (evolocumab) reduced the risk of death by 20% in more than 12,000 high-risk patients who had not previously suffered a heart attack or stroke. The Phase 3 VESALIUS-CV findings could support broader use of the cholesterol drug, increase physician adoption and strengthen one of Amgen’s key revenue drivers. Amgen Repatha clinical results
• Positive Sentiment: Analysts are raising earnings expectations. Erste Group Bank increased its FY2027 EPS forecast to $24.43 from $23.50, above the broader consensus estimate of $22.97. The revision follows Amgen’s recent quarterly earnings and revenue beat, along with higher full-year guidance, reinforcing the company’s favorable earnings momentum. Erste Group Bank earnings forecast
• Positive Sentiment: Investor attention is increasing around Amgen’s cardiovascular opportunity. Jim Cramer highlighted Repatha as a largely overlooked drug that could address a very large market, potentially comparable in importance to major obesity-drug markets over time. While this is commentary rather than a fundamental forecast, it adds to the bullish narrative surrounding Repatha. Jim Cramer on Amgen’s Repatha opportunity
• Neutral Sentiment: Relative performance remains favorable, but valuation is being debated. Reports note that AMGN has outperformed the broader market and other general drug manufacturers, while analysts remain moderately bullish. However, the stock’s strong run and elevated valuation could limit additional upside unless earnings and product growth continue to accelerate. Amgen stock performance compared with drug manufacturers
• Negative Sentiment: UK regulators suspended Tavneos for new patients. Britain’s medicines regulator cited unreliable data from the main study supporting approval of the rare-disease drug and suspended its use and sale for new patients. The action creates regulatory, reputational and potential revenue risks, although Tavneos is smaller than Amgen’s major commercial products. UK regulator Tavneos suspension

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.